First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level

Key Points

• To evaluate the effectiveness of tagraxofusp as a first-line treatment in blastic plasmacytoid dendritic cell neoplasm.
• Administered tagraxofusp to adults diagnosed with blastic plasmacytoid dendritic cell neoplasm.
• Assessed patient responses and survival rates.
• Included patients with varying fitness levels.
• Patients showed durable responses to tagraxofusp treatment.
• Prolonged survival was observed regardless of fitness level.

Abstract